After a four-year investment period, SHS Capital sells its shares in Betterguards Technology GmbH to Hochpfiffig GmbH Betterguards has developed a platform technology that protects human joints from ligament and tendon injuries Betterguards products are used in orthopaedic technology, occupational safety and also in the field of professional sports Tübingen / 14.12.2023 SHS Capital is […]

We are delighted to support the Felix Neureuther Foundation for more exercise for children and young people with our donation this year. The scientifically based exercise programme “Beweg dich schlau! mit Felix Neureuther” (BDS) aims to convey the joy of exercise and lay the foundations for a health-oriented life as early as possible. Physical health, […]

Once again this year, part of the SHS Capital team took part in the Tübingen St Nicholas Run. On 3 December, the St Nicholas Run, sponsored by itdesign GmbH among others, took place in Tübingen for the 48th time. Almost 2,750 participants successfully completed the half marathon. After the run, the participants enjoyed to lunch […]

Marie joined SHS at the beginning of September 2023. Marie began her studies with a Bachelor’s degree in European Economic Studies at the University of Bamberg, including a year abroad at Excelia Business School in La Rochelle, France. This was followed by a Master’s degree in Banking & International Finance at Toulouse Business School. Her […]

ESSERT Robotics was recently honored with the prestigious FANUC Innovation Award. The award was presented at the Robot Global Partner of the Year event in Tokyo, Japan. The ESSERT MicroFactory, an innovative and flexible production line, was recognized as a pioneering solution for Industry 4.0. The Award is one of the most prestigious awards and […]

We are pleased to announce that the Next Generation Sequencing technology used by our SHS Capital portfolio company PathoQuest for the safety of biologics has been highlighted in the ICHQ5A(R2) guideline adopted in November 2023. This global guideline is an important regulatory standard for the market. It states: “NGS is favoured as a replacement for […]

We are pleased to announce that our SHS Capital portfolio company CoreMedic has announced the successful first-in-human transcatheter application of its ChordArt Mitral Valve Vision Repair System. The patient, who suffered from severe degenerative mitral regurgitation due to a mitral valve leaflet, was successfully treated with the ChordArt TMVr system as part of CoreMedic’s first-in-human […]

As in previous years, SHS once again hosted an Alumni BBQ at the Tübingen office in late summer. During a joint aperitif followed by a barbecue, former and current SHS interns were able to exchange ideas with each other and with the SHS team. We are pleased that many of our former interns are now […]

Hannes Kempter joined the SHS team in May 2023. Hannes holds a German-French Bachelor’s degree from ESB and CESEM, followed by a Master’s degree in Finance from WHU, including a semester abroad in Florida. He started his career in the M&A team at the investment bank Raymond James. There, his focus from day one was […]

Paris-based SHS portfolio company PathoQuest SAS is a leader in the development and delivery of next-generation sequencing (NGS) tests for biopharmaceuticals. PathoQuest recently published a study with Charles River Laboratories International Inc. showing that PathoQuest’s GMP-compliant, NGS-based test demonstrates greater ability to detect viral contamination compared to in vivo tests. The aim of the study […]

The Baden-Württemberg-based robotics company ESSERT GmbH, which has been part of the SHS portfolio since August 2023 and specialises in the development of intelligent automation solutions for a wide range of application areas with a focus on the pharmaceutical, life science and general industry sectors, has won the prestigious ISPE RAYA Award together with Vetter […]

Pharmaceutical company AMW recently announced that it has achieved a key milestone in opening up new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant. The active ingredient goserelin is a synthetic peptide that can be used primarily in the treatment […]